Trial Profile
A retrospective, multicentre study of Melphalan-PHP in patients with uveal melanoma undergoing percutaneous hepatic perfusion with melphalan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jan 2018
Price :
$35
*
At a glance
- Drugs Melphalan (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 12 Jan 2018 New trial record
- 09 Jan 2018 Results published in the Media Release